We report the results from a multicenter retrospective study of 69 adult patients who underwent haploidentical blood or marrow transplantation (haplo-BMT) with post-transplantation cyclophosphamide (PTCy) for chronic phase myelofibrosis. The median age at BMT was 63 years (range, 41–74). Conditioning regimens were reduced intensity in 54% and nonmyeloablative in 39%. Peripheral blood grafts were used in 86%. The median follow-up was 23.1 months (range, 1.6–75.7). At 3 years, the overall survival, relapse-free survival (RFS), and graft-versus-host-disease (GVHD)-free-RFS were 72% (95% CI 59–81), 44% (95% CI 29–59), and 30% (95% CI 17–43). Cumulative incidences of non-relapse mortality and relapse were 23% (95% CI 14–34) and 31% (95% CI 17–47) at 3 years. Spleen size ≥22 cm or prior splenectomy (HR 6.37, 95% CI 2.02–20.1, P = 0.002), and bone marrow grafts (HR 4.92, 95% CI 1.68–14.4, P = 0.004) were associated with increased incidence of relapse. Cumulative incidence of acute GVHD grade 3–4 was 10% at 3 months and extensive chronic GVHD was 8%. Neutrophil engraftment was reported in 94% patients, at a median of 20 days (range, 14–70). In conclusion, haplo-BMT with PTCy is feasible in patients with myelofibrosis. Splenomegaly ≥22 cm and bone marrow grafts were associated with a higher incidence of relapse in this study.

我们报告了一项多中心回顾性研究的结果，该研究纳入了 69 名接受半相合血液或骨髓移植 (haplo-BMT) 和移植后环磷酰胺 (PTCy) 治疗慢性期骨髓纤维化的成年患者。BMT 的中位年龄为 63 岁（范围 41-74 岁）。54% 的调理方案强度降低，39% 的调理方案为非清髓性。86% 的患者使用了外周血移植物。中位随访时间为 23.1 个月（范围 1.6–75.7）。3 年时，总生存率、无复发生存率 (RFS) 和无移植物抗宿主病 (GVHD) 的 RFS 分别为 72% (95% CI 59–81)、44% (95% CI 29) –59) 和 30% (95% CI 17–43)。3 年时非复发死亡率和复发的累积发生率为 23%（95% CI 14-34）和 31%（95% CI 17-47）。脾脏大小≥22 cm 或之前进行过脾切除术（HR 6.37，95% CI 2.02–20.1，P = 0.002）和骨髓移植（HR 4.92，95% CI 1.68–14.4，P  = 0.004）与复发率增加相关。3 个月时急性 GVHD 3-4 级的累积发生率为 10%，广泛的慢性 GVHD 为 8%。94% 的患者报告了中性粒细胞植入，中位时间为 20 天（范围，14-70）。总之，具有 PTCy 的单倍体 BMT 在骨髓纤维化患者中是可行的。在这项研究中，脾肿大 ≥ 22 cm 和骨髓移植与较高的复发率相关。